WVE
Wave Life SciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Post-selloff valuation now leans heavily on whether Wave can re-center the story on WVE-006 and on a cleaner Phase 2 obesity setup. The best bull path is a solid ATS WVE-006 update plus successful Phase 2a initiation for WVE-007, with cash runway into 3Q 2028 buying time for both.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +5.8.
What can break
Biotech sentiment can stay weak even with adequate cash runway if catalysts remain early-stage and binary.
Momentum
3
Value
41
Sentiment
83
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $6.80 · Bull $13.50 · Bear $3.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $34.78
Why
Momentum3 · Δ7d +0.1
Value41 · Δ7d +0.1
Sentiment83 · Δ7d +5.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
3
34% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
83
33% active weight
Current posture
7d trendImproving
Δ7d
+5.8
Δ21d
+22.6
Why this grade
Composite grade D. Momentum 2.9 / Value 41.1 / Sentiment 82.5
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.09B
Beta
-1.77
Shares Out
182.74M
P/E (TTM) · Derived
-4.9
P/S (TTM)
25.10
P/FCF (TTM) · Derived
-4.96
Rev YoY
+199.1%
EPS YoY
+31.1%
Gross Margin
-
Op Margin
-124.5%
Net Debt
-$302.08M
Current Ratio
2.51
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology